Press Releases

Date Title  
Toggle Summary Natera to Present New Data at ASN Kidney Week 2020 Showing Clinical Differentiation of the Prospera™ Test
Represents largest dd-cfDNA retransplant study to date and demonstrates clinical value of proprietary background cfDNA technology SAN CARLOS, Calif. , Oct. 21, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present
Toggle Summary Natera Teams Up with the George Lopez Foundation on the #GLFTrickShot Kidney Disease Awareness Challenge
Celebrities and the public are making creative golf trick shot videos to create awareness and encourage donations for kidney disease patients SAN CARLOS , Calif. and LOS ANGELES , Oct. 5, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced
Toggle Summary Court Rejects ArcherDX's Motion to Dismiss Natera's Patent Infringement Case
Upholds validity of Natera's patents; patent case against ArcherDX continues SAN CARLOS, Calif. , Oct. 5, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reports that the U.S. District Court of Delaware has rejected all of ArcherDX's
Toggle Summary Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test Positive with Signatera™
SAN CARLOS, Calif. , Oct. 2, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced that its  Signatera molecular residual disease (MRD) test will be used in the DARE study, a multi-center clinical trial of palbociclib (IBRANCE®), a CDK4/6
Toggle Summary Medicare Issues Draft Local Coverage Determination for Signatera™ in Immunotherapy Response Monitoring
Proposes expanded coverage of the Signatera minimal residual disease (MRD) test in a broad range of solid tumor types and indications including immunotherapy (IO) monitoring SAN CARLOS, Calif. , Sept. 24, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free
Toggle Summary Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting
1 oral and 3 poster presentations demonstrate effectiveness of Signatera™ in stage IV oligometastatic colorectal cancer (CRC), stage I-III CRC, and esophageal adenocarcinomas SAN CARLOS, Calif. , Sept. 18, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free
Toggle Summary Natera Launches Initiative to Transform the Management of Cancer Patients in Organ Transplantation
Innovative technology platform for cell-free DNA testing in oncology and organ transplantation uniquely positions Natera to help improve outcomes for the most vulnerable transplant patients SAN CARLOS, Calif. , Sept. 14, 2020 /PRNewswire/ --  Natera, Inc.
Toggle Summary Natera's Signatera™ MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer
SAN CARLOS, Calif. , Sept. 11, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, the Medicare Administrative Contractor (MAC) for Northern California , has finalized a final local coverage article (LCA) to provide
Toggle Summary Natera Announces Pricing of Follow-On Offering
SAN CARLOS, Calif. , Sept. 10, 2020 /PRNewswire/ --  Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 4,166,666 shares of its common stock at a price to the public of $60.00 per share.
Toggle Summary Natera to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
SAN CARLOS, Calif. , Sept. 10, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Morgan Stanley 18th Annual Global Healthcare Conference taking place virtually on Monday, Sept.

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.